Neoadjuvant hormonal therapy in carcinoma of the prostate

BJU International

Volumn 83, Issue 4, 1999, Pages 438-448

  Lee, H H K ^a   Warde, P ^a   Jewett, M A S ^b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Androgen ablation; Hormonal therapy; Prostate cancer; Radiation therapy; Radical prostatectomy; Recurrence; Survival

Indexed keywords

ANTIANDROGEN; CYPROTERONE ACETATE; ESTRAMUSTINE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; TRIPTORELIN;

CANCER ADJUVANT THERAPY; DOSIMETRY; HORMONAL THERAPY; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS, HORMONAL; HUMANS; MALE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 0033051997     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-410X.1999.00953.x     Document Type: Review

References (81)

1. 1 Anonymous. Canadian Cancer Statistics 1997. Toronto: National Cancer Institute of Canada 1997
2. 2 Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27
3. 3 Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1998. CA Cancer J Clin 1998; 48: 6-29
4. 4 Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996; 46: 5-27
5. 5 Schroder FH. Prostate cancer: to screen or not to screen? Br Med 1993; 306: 407-8
6. 6 Lange PH, Narayan P. Understaging and undergrading of prostate cancer. Urology 1983; 21: 113-8
7. 7 Anscher MS, Prosnitz LR. Postoperative radiotherapy for patients with carcinoma of the prostate undergoing radical prostatectomy with positive surgical margins, seminal vesicle involvement and/or penetration through the capsule. J Urol 1407-12; 1987: 138:
8. 8 Bigg SW, Kavoussi LR, Catalona WS. Role of nerve-sparing radical prostatectomy for clinical stage B2 prostate cancer. J Urol 1990; 144: 1420-4
9. 9 Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long-term (15 years) results after radical prostatectomy for clinically localised (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-7
10. 10 Paulson DF. Impact of radical prostatectomy in the management of clinically localised disease. J Urol 1994; 152: 1826-31
11. 11 Epstein JI. Incidence and significance of positive margins in radical prostatectomy specimens. Urol Clin North Am 1996; 23: 651-63
12. 12 Lu-Yao GL, McLerran D, Wasson J. Wennberg JE. An assessment of radical prostatectomy. J Am Med Assoc 1993; 269: 2633-6
13. 13 Ritvo P, Krahn M, Magistretti A, Irvine MJ, Naglie G, Trachtenberg J. Comprehensively assessing the burden of prostate cancer. Can J Urol 1996; 3: 1-5
14. 14 Maurer HM, Beltangady M, Gehan EA et al. The Intergroup Rhabdomyosarcoma Study. I. A final report. Cancer 1988; 61: 209-20
15. 15 Maurer HM, Gehan EA, Beltangady M et al. The Intergroup Rhabdomyosarcoma Study . II. Cancer 1993; 71: 1904-22
16. 16 Crist W, Gehan EA, Ragab AH et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol 1995; 13: 610-30
17. 17 Duffner PK, Horowitz ME, Krischer JP et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. New Engl J Med 1993; 328: 1725-31
18. 18 Hoffman HJ. Effects of medulloblastoma resections on outcome in children: a report from the Children's Cancer Group - Comment. Neurosurgery 1996; 38: 271
19. 19 Einhorn LH. Current chemotherapy strategy in patients with germ cell tumors. Eur Urol 1993; 23: 47-8
20. 20 Matthay KK. Neuroblastoma: a clinical challenge and biologic puzzle. CA Cancer J Clin 1995; 45: 179-92
21. 21 Matthay KK, O'Leary MC, Ramsay NK et al. Role of myeloablative therapy in improved outcome for high risk neuroblasloma: review of recent Children's Cancer Group results. Eur J Cancer 1995; 31A: 572-5
22. 22 Greenberg M, Burnweit C, Filler R et al. Preoperative chemotherapy for children with Wilms' tumor. J Paediat Surg 1991; 26: 949-53
23. 23 Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol 1996; 14: 3156-74
24. 24 Coffey DS. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. In: Walsh PC, Retik AB. Stamey TA, Vaughan ED Jr, eds, Campbell's Urology, 6th edn. Philadelphia: WB Saunders, 1992: 221-66
25. 25 Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostate cancer to androgen ablation therapy as studied in the Dunning R-3327 H adenocarcinoma. Cancer Res 1981; 41: 5070-5
26. 26 Kyprianou N, English HF, Isaacs JT. Programmed cell death during regression of PC-82 human prostate cancer following androgen ablation. Cancer Res 1990; 50: 3748-53
27. 27 Denmeade SR, Lin XS, Isaacs JT. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate 1996; 28: 251-65
28. 28 Labrie F, Veilleux R. A wide range of sensitivities to androgens develops in cloned Shionogi mouse mammary tumor cells. Prostate 1986; 8: 293-300
29. 29 Hsieh W-S, Simons JW. Systemic therapy of prostate cancer tumor biology. Cancer Treat Rev 1993; 19: 229-60
30. 30 Wilding G. Endocrine control of prostate cancer. Cancer Surv 1995; 23: 43-62
31. 31 Newmark JR, Hardy DO, Tomb DC et al. Androgen receptor gene mutations in human prostate cancer. Proc Natl Acad Sci USA 1992; 89: 6319-23
32. 32 Aprikian AG. Molecular basis of androgen blockade in prostate cancer. Can J Urol 1996; 3: 235-9
33. 33 Scher HI, Zhang AF, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. Urology 1996; 47: 61-9
34. 34 Visakorpi T, Hyytinen E, Koivisto P et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9: 401-6
35. 35 Koivisto P, Kononen J, Palmberg C et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57: 314-9
36. 36 Pilepich MV, Krall JM, John MJ et al. Hormonal cytoreduction in locally advanced carcinoma of the prostate treated with definitive radiotherapy: preliminary results of RTOG 83-07. Int J Radiat Oncol Biol Phys 1989; 16: 813-7
37. 37 Shearer RJ, Davies JH, Gelister JSK, Dearnaley DP. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol 1992; 69: 521-4
38. 38 Zelefsky MJ, Leibel SA, Burman CM et al. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 1994; 29: 755-61
39. 39 Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF. Neoadjuvant hormonal downsizing of localised carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 1995; 13: 8-15
40. 40 Yang FE, Chen GTY, Ray P et al. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys 1995; 33: 1009-17
41. 41 Widmark A, Damber J-E, Bergh A, Henriksson R. Estramustine potentiates the effects of irradiation on the Dunning R3327 rat prostatic adenocarcinoma. Prostate 1994; 24: 79-83
42. 42 Nakfoor BM, Prince EA, Shipley WU, Zietman AL. A randomised trial comparing local tumor control following irradiation alone versus combined androgen withdrawal and irradiation in an androgen sensitive prostate cancer xenograft. Int J Radiat Oncol Biol Phys 1995; 32: A97
43. 43 Zietman AL, Nakfoor BM, Prince EA, Gerweck LE. The effect of androgen deprivation and radiation therapy on an androgen-sensitive murine tumor: an in vitro and in vivo study. Cancer J Sci Am 1997; 3: 31-6
44. 44 Green N, Bodner H, Broth E et al. Improved control of bulky prostate carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys 1984; 10: 971-6
45. 45 Pilepich MV, John MJ, Krall JM, McGowan D, Hwang YS, Perez CA. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and Zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Am J Clin Oncol 1990; 13: 461-4
46. 46 Pollack A, Zagars GK, Kopplin S. Radiotherapy and androgen ablation for clinically localised high-risk prostate cancer. Int J Radiat Oncol Biol Phys 1995; 32: 13-20
47. 47 Pilepich MV, Krall JM, Sause WT et al. Prognostic factors in carcinoma of the prostate - analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys 1987; 13: 339-49
48. 48 Pilepich MV, Krall JM, Al-Sarraf M et al. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma: a randomised comparative trial of the Radiation Therapy Oncology Group. Urology 1995; 45: 616-23
49. 49 Pilepich M, Winter K, Roach M et al. Phase III Radiation Therapy Oncology Group (RTOG) trial of androgen deprivation before and during radiotherapy 86-10 in locally advanced carcinoma of the prostate. Proc Am Soc Clin Oncol 1998; 17: A1185
50. 50 Laverdiere J, Gomez JL, Cusan L et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localised prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 247-52
51. 51 Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997; 337: 295-300
52. 52 Isaacs W, Carter B, Ewing C. Wild type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Concer Res 1991; 51: 4716-20
53. 53 Heidenberg H, Sesterhenn I, Gaddipati J et al. Alteration of tumor suppressor gene p53 in a high fraction of hormone refractory prostate cancer. J Urol 1995; 154: 414-21
54. 54 Stattin P, Damber J, Modig H, Bergh A. Pretreatment p53 immunoreactivity does not confer radioresistance in prostate cancer patients. Int J Radiat Oncol Biol Phys 1996; 35: 885-9
55. 55 McDonnell T, Deane N, Platt F et al. bcl-2 immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88
56. 56 McDonnell T, Nunez G, Platt F et al. Deregulated bcl-2 immunoglobulin transgene expands a resting but responsive immunoglobulin M and D-expressing B-cell population. Mol Cell Biol 1990; 10: 1901-7
57. 57 MacFarlane MT, Abi-Aad A, Stein A, Danella J, Belldegrun A, de Kernion JB. Neoadjuvant hormonal deprivation in patients with locally advanced prostate cancer. J Urol 1993; 150: 132-4
58. 58 Scott WW, Boyd HL. Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: a retrospective study based upon 25 years of experience. J Urol 1969; 101:86-92
59. 59 Monfette G, Dupont A, Labrie F. Temporary combination therapy with flutamide and Tryptex as adjuvant to radical prostatectomy for the treatment of early stage prostate cancer. In Labrie F, Lee F, Dupont A, eds, Early Stage Prostate Cancer: Diagnosis and Choice of Therapy. New York: Elsevier Science Publishers BV, 1989: 41-51
60. 60 Soloway MS. Use of an LH-RH analog prior to radical prostatectomy. Proc Am Soc Clin Oncol 1989; 8: A542
61. 61 Soloway MS, Hachiya TS, Ruiz HE, Gomez CC, Civantos F. Significance of androgen deprivation prior to radical prostatectomy, with special reference to prostate specific antigen. World J Urol 1993; 11: 221-6
62. 62 Fair WR, Aprikian A, Sogani P, Reuter VF, Whitmore WR Jr. The role of neoadjuvant hormonal manipulation in localised prostate cancer. Cancer 1993; 71: 1031-8
63. 63 Solomon MH, McHugh TA, Dorr RP. Hormone ablation treatment as neoadjuvant therapy prior to radical prostatectomy. Clin Invest Med 1993; 16: 532-8
64. 64 Schulman CC, Sassine AM. Neoadjuvant hormonal deprivation before radical prostatectomy. Clin Invest Med 1993; 16: 523-31
65. 65 Oesterling JE, Andrews PE, Suman VJ, Zincke H, Myers RP. Preoperative androgen deprivation therapy: artificial lowering of serum prostate specific antigen without downstaging the tumor. J Urol 1993; 149: 779-82
66. 66 Labrie F, Cusan L, Gomez JL et al. Downstaging of early stage prostate cancer before radical prostatectomy: the first randomised trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 1994: 44: 29-37
67. 67 Van Poppel H, De Ridder D, Elgamal AA et al. Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomised trial. J Urol 1995; 154: 429-34
68. 68 Hugosson J, Abrahamsson PA, Ahlgren G et al. The risk of malignancy in the surgical margin at radical prostatectomy reduced almost three-fold in patients given neo-adjuvant hormone treatment. Eur Urol 1996; 29: 413-9
69. 69 Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr. Puras-Baez A. Randomised prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B (T2bNxM0) prostate cancer. J Urol 1995; 154: 424-8
70. 70 Goldenberg SL, Klotz LH, Srigley J et al. Randomised, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localised prostate cancer. J Urol 1996; 156: 873-7
71. 71 Fair WR, Aprikian AG, Cohen D, Sogani P, Reuter V. Use of neoadjuvant androgen deprivation therapy in clinically localised prostate cancer. Clin Invest Med 1993; 16: 516-22
72. 72 Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate-specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J Urol 1993; 149: 516-8
73. 73 Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993; 71: 3582-93
74. 74 Rabbani F, Sullivan LD, Goldenberg SL, Stothers L. Neoadjuvant androgen deprivation before radical prostatectomy: who is unlikely to benefit. Br J Urol 1997; 79: 221-5
75. 75 Aus G, Hugosson J, Abrahamsson P-A et al. Pretreatment with triptorelin before radical prostatectomy - a 3 year follow-up. J Urol 1997; 157: A1540
76. 76 Soloway MS, Sharifi R, Wajsman Z et al. Randomised prospective study - radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - initial results. J Urol 1996; 155: A976
77. 77 Soloway M, Sharifi R, Wajsman Z et al. Radical prostatectomy alone vs radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24 month results. J Urol 1997; 157: A619
78. 78 Klotz LH, Goldenberg SL, Bullock MJ, Srigley JR, Laplante S. and the Canadian Uro-Oncology Group. Neoadjuvant cyproterone acetate (CPA) therapy prior to radical prostatectomy reduces tumour burden and margin positivity without altering 6 and 12 month post-treatment PSA. results of a randomised trial. J Urol 1996; 155: A356
79. 79 Goldenberg SL, Klotz L, Jewett M et al. A randomised trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24 month post-treatment PSA results. J Urol 1997; 157: A357
80. 80 Gleave ME, Goldenberg SL, Jones EC, Bruchovsky N, Sullivan LD. Biochemical and pathological effects of 8 months of neoadjuvant withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996; 155: 213-9
81. 81 Gleave M, Goldenberg SL, Jones E, Bruchovsky N, Sullivan L. Biochemical and pathological effects of eight months of neoadjuvant androgen withdrawal therapy - an update on 125 consecutive patients. J Urol 1997; 157: A1530